Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPEREIRA, F. A.
dc.contributor.authorMATTAR, R.
dc.contributor.authorFACINCANI, I.
dc.contributor.authorDEFINO, H. L. A.
dc.contributor.authorRAMALHO, L. N. Z.
dc.contributor.authorJORGETTI, V.
dc.contributor.authorVOLPON, J. B.
dc.contributor.authorPAULA, F. J. A. de
dc.date.accessioned2013-07-30T17:17:38Z
dc.date.available2013-07-30T17:17:38Z
dc.date.issued2012
dc.description.abstractOsteoporosis is a major complication of chronic cholestatic liver disease (CCLD). We evaluated the efficacy of using disodium pamidronate (1.0 mg/kg body weight) for the prevention (Pr) or treatment (Tr) of cholestasis-induced osteoporosis in male Wistar rats: sham-operated (Sham = 12); bile duct-ligated (Bi = 15); bile duct-ligated animals previously treated with pamidronate before and 1 month after surgery (Pr = 9); bile duct-ligated animals treated with pamidronate 1 month after surgery (Tr = 9). Rats were sacrificed 8 weeks after surgery. Immunohistochemical expression of IGF-I and GH receptor was determined in the proximal growth plate cartilage of the left tibia. Histomorphometric analysis was performed in the right tibia and the right femur was used for biomechanical analysis. Bone material volume over tissue volume (BV/TV) was significantly affected by CCLD (Sham = 18.1 +/- 3.2 vs Bi = 10.6 +/- 2.2%) and pamidronate successfully increased bone volume. However, pamidronate administered in a preventive regimen presented no additional benefit on bone volume compared to secondary treatment (BV/TV: Pr = 39.4 +/- 12.0; Tr = 41.2 +/- 12.7%). Moreover, the force on the momentum of fracture was significantly reduced in Pr rats (Sham = 116.6 +/- 23.0; Bi = 94.6 +/- 33.8; Pr = 82.9 +/- 22.8; Tr = 92.5 +/- 29.5 N; P < 0.05, Sham vs Pr). Thus, CCLD had a significant impact on bone histomorphometric parameters and pamidronate was highly effective in increasing bone mass in CCLD; however, preventive therapy with pamidronate has no advantage regarding bone fragility.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP [06/56890-0]
dc.description.sponsorshipCNPq
dc.description.sponsorshipFAEPA
dc.identifier.citationBRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.45, n.12, p.1255-1261, 2012
dc.identifier.doi10.1590/S0100-879X2012007500143
dc.identifier.issn0100-879X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1303
dc.language.isoeng
dc.publisherASSOC BRAS DIVULG CIENTIFICA
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsopenAccess
dc.rights.holderCopyright ASSOC BRAS DIVULG CIENTIFICA
dc.subjectOsteoporosis pathogenesis
dc.subjectGrowth factors
dc.subjectBiomechanics
dc.subjectAnimal models
dc.subjectPamidronate
dc.subject.othermetabolic bone-disease
dc.subject.otherpostmenopausal osteoporosis
dc.subject.otherhepatic osteodystrophy
dc.subject.othervertebral fractures
dc.subject.otherrandomized-trial
dc.subject.othercirrhosis
dc.subject.otherbisphosphonate
dc.subject.otherwomen
dc.subject.otherrisedronate
dc.subject.otherchildren
dc.subject.wosBiology
dc.subject.wosMedicine, Research & Experimental
dc.titlePamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalPEREIRA, F. A.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-14049900 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalMATTAR, R.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-14049900 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalFACINCANI, I.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat & Neonatol, BR-14049900 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalDEFINO, H. L. A.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biomecan Med & Reabilitacao Aparelho Locomot, BR-14049900 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalRAMALHO, L. N. Z.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Patol, BR-14049900 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalVOLPON, J. B.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biomecan Med & Reabilitacao Aparelho Locomot, BR-14049900 Ribeirao Preto, SP, Brazil
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcVANDA JORGETTI
hcfmusp.contributor.author-fmusphcFLAVIO JOTA DE PAULA
hcfmusp.description.beginpage1255
hcfmusp.description.endpage1261
hcfmusp.description.issue12
hcfmusp.description.volume45
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22983176
hcfmusp.origem.scieloSCIELO:S0100-879X2012001200021
hcfmusp.origem.scopus2-s2.0-84872357986
hcfmusp.origem.wosWOS:000312461700021
hcfmusp.publisher.citySAO PAULO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceBachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008-1531
hcfmusp.relation.referenceBlack DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
hcfmusp.relation.referenceBlack DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
hcfmusp.relation.referenceBurr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756-3282(01)00619-6
hcfmusp.relation.referenceCAPRA F, 1991, ITAL J GASTROENTEROL, V23, P124
hcfmusp.relation.referenceCHAPPARD D, 1989, PATHOL RES PRACT, V184, P480
hcfmusp.relation.referenceChen CC, 1996, J GASTROEN HEPATOL, V11, P417, DOI 10.1111/j.1440-1746.1996.tb00284.x
hcfmusp.relation.referenceCourtland HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014762
hcfmusp.relation.referenceCrawford BAL, 2003, OSTEOPOROSIS INT, V14, P987, DOI 10.1007/s00198-003-1495-z
hcfmusp.relation.referenceElis S, 2010, J BONE MINER RES, V25, P1257, DOI 10.1002/jbmr.20
hcfmusp.relation.referenceEriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756-3282(02)00869-4
hcfmusp.relation.referenceGasser Rudolf W, 2008, Wien Med Wochenschr, V158, P553, DOI 10.1007/s10354-008-0594-z
hcfmusp.relation.referenceGoral V, 2010, WORLD J GASTROENTERO, V16, P1639, DOI 10.3748/wjg.v16.i13.1639
hcfmusp.relation.referenceGrossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
hcfmusp.relation.referenceGUANABENS N, 1990, AM J GASTROENTEROL, V85, P1356
hcfmusp.relation.referenceHorton JA, 2008, ANAT REC, V291, P283, DOI 10.1002/ar.20650
hcfmusp.relation.referenceJORGEHERNANDEZ JA, 1988, DIGEST DIS SCI, V33, P1089, DOI 10.1007/BF01535783
hcfmusp.relation.referenceKippo K, 1998, J BONE MINER RES, V13, P287, DOI 10.1359/jbmr.1998.13.2.287
hcfmusp.relation.referenceKippo K, 1997, CALCIFIED TISSUE INT, V61, P151, DOI 10.1007/s002239900314
hcfmusp.relation.referenceLi J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
hcfmusp.relation.referenceLopez-Larramona German, 2011, World J Hepatol, V3, P300, DOI 10.4254/wjh.v3.i12.300
hcfmusp.relation.referenceMiller PD, 2008, BEST PRACT RES CL EN, V22, P849, DOI 10.1016/j.beem.2008.07.004
hcfmusp.relation.referenceMonegal A, 1997, CALCIFIED TISSUE INT, V60, P148
hcfmusp.relation.referenceOkuda S, 2001, SPINE, V26, P2421, DOI 10.1097/00007632-200111150-00005
hcfmusp.relation.referenceOlson LE, 2011, CALCIFIED TISSUE INT, V88, P1, DOI 10.1007/s00223-010-9436-2
hcfmusp.relation.referencePARFITT AM, 1987, J BONE MINER RES, V2, P595
hcfmusp.relation.referencePENG Z, 1994, BONE, V15, P523, DOI 10.1016/8756-3282(94)90276-3
hcfmusp.relation.referencePereira FA, 2009, CALCIFIED TISSUE INT, V85, P75, DOI 10.1007/s00223-009-9249-3
hcfmusp.relation.referenceReginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
hcfmusp.relation.referenceRosen CJ, 2012, NAT MED, V18, P202, DOI 10.1038/nm.2630
hcfmusp.relation.referenceTaveira ATA, 2010, BRAZ J MED BIOL RES, V43, P1127, DOI 10.1590/S0100-879X2010007500118
hcfmusp.relation.referenceTaveira ATA, 2007, CLIN ENDOCRINOL, V66, P518, DOI 10.1111/j.1365-2265.2007.02765.x
hcfmusp.relation.referenceThornton J, 2008, HEALTH TECHNOL ASSES, V12, P1
hcfmusp.relation.referenceTOOLAN BC, 1992, J BONE MINER RES, V7, P1399
hcfmusp.relation.referenceTurner A. Simon, 2001, European Cells & Materials, V1, P66
hcfmusp.relation.referenceYang KY, 2007, YONSEI MED J, V48, P653, DOI 10.3349/ymj.2007.48.4.653
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication43722089-d1f9-4d2c-98df-79d676fb6a5a
relation.isAuthorOfPublicationb2ada530-b551-4f01-9c58-c1f1790c8dd2
relation.isAuthorOfPublication.latestForDiscovery43722089-d1f9-4d2c-98df-79d676fb6a5a
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_JORGETTI_Pamidronate_for_the_treatment_of_osteoporosis_secondary_to_2012.PDF
Tamanho:
1.26 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16